Raw Material Shortages – Midas is actively approaching these challenges
In the recent years, generic drug shortages have been raised increasing attention in the EU. The reasons for these drug shortages are manifold. They could be caused by quality issues at a key supplier, unexpected increase of demand for a certain product, price pressure leading to strategy changes/ outsourcing activities or incidents causing production stops in the chemical supply chain.
Although there might be a large number of manufacturers for a certain API, these are often directly or indirectly dependent on just a few raw material / starting material suppliers. In case of an incident at the raw material supplier, it might have an impact on the API availability in the whole market.
We are looking forward to an exchange about your ideas, please get in contact with us!
- Are you interested in intermediates / raw materials that are short in the market? We might be working on a solution already.
- Do you intend to minimize risks in your supply chain by adding a sustainable source from a different territory?
- Do you hold technologies of interest for the EU-market or are you based in EU and consider to re-activate a formerly stopped technology? We are open to discuss about joint transfer activities and/or a marketing cooperation.